Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

War on Cancer /
How should decision makers assess the value of a medicine?

20th Oct 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.10.15
Views: 1599

Dr Hans-Georg Eichler - Senior Medical Officer, European Medicines Agency

Dr Eichler talks to ecancertv at the War On Cancer Meeting about 'medicine adaptive pathways' and the difficulties in assessing the appropriateness of different drugs.

He notes the difficulty in balancing the desire for the most up-to-date treatments, versus the importance of tried and tested treatments which we know more about in deciding the value of a given medicine.

Value is measured in clinical benefit as well as financial and the rate at which new treatments are explored is driven, he argues, by the insistence of patients on improvements. At the same time, patient's health cannot be put at risk by un-vetted drugs.

He argues that finding the most effective evidence-based method of assessment and license modification is a 'journey' and that though some level of uncertainty will need to be accepted, it will diminish over time.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation